The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys

Parkinsonism and Related Disorders

Volumn 17, Issue 4, 2011, Pages 270-276

  Grégoire, Laurent ^a,b   Morin, Nicolas ^a,b   Ouattara, Bazoumana ^a,b   Gasparini, Fabrizio ^c   Bilbe, Graeme ^c   Johns, Donald ^c   Vranesic, Ivo ^c   Sahasranaman, Srikumar ^d   Gomez Mancilla, Baltazar ^c   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

AFQ056; Dyskinesia; Levodopa; MGluR5; MPTP monkey; Parkinson

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AFQ 056; ANTIPARKINSON AGENT; GLUTAMATE RECEPTOR 5; GLUTAMIC ACID; LEVODOPA; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DYSKINESIA; EXPERIMENTAL MONKEY; FEMALE; LOCOMOTION; LOW DRUG DOSE; MACACA FASCICULARIS; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT DURATION;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; PARKINSONIAN DISORDERS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 79954995144     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.01.008     Document Type: Article

References (30)

1. Guigoni C., Aubert I., Li Q., Gurevich V.V., Benovic J.L., Ferry S., et al. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Rel Disord 2005, 11:S25-S29.
2. Van Gerpen J.A., Kumar N., Bower J.H., Weigand S., Ahlskog J.E. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006, 63:205-209.
3. Calon F., Rajput A.H., Hornykiewicz O., Bedard P.J., Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 2003, 14:404-416.
4. Chase T.N., Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000, 23:S86-S91.
5. Stocchi F., Tagliati M., Olanow C.W. Treatment of levodopa-induced motor complications. Mov Disord 2008, 23:S599-S612.
6. Hadj Tahar A., Gregoire L., Darre A., Belanger N., Meltzer L., Bedard P.J. Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis 2004, 15:171-176.
7. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
8. Meldrum B.S. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000, 130:1007S-1015S.
9. Fuxe K., Marcellino D., Rivera A., Diaz-Cabiale Z., Filip M., Gago B., et al. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res Rev 2008, 58:415-452.
10. Pisani A., Calabresi P., Centonze D., Bernardi G. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol 1997, 120:1007-1014.
11. Conn P.J., Battaglia G., Marino M.J., Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005, 6:787-798.
12. Mela F., Marti M., Dekundy A., Danysz W., Morari M., Cenci M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 2007, 101:483-497.
13. Johnston T.H., Fox S.H., McIldowie M.J., Piggott M.J., Brotchie J.M. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Therapeut 2010, 333:865-873.
14. Morin N., Gregoire L., Gomez-Mancilla B., Gasparini F., Di Paolo T. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010, 58:981-986.
15. Samadi P., Gregoire L., Morissette M., Calon F., Hadj Tahar A., Dridi M., et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 2008, 29:1040-1051.
16. Ouattara B., Gregoire L., Morissette M., Gasparini F., Vranesic I., Bilbe G., et al. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 2009, Published online 24 December 2009. 10.1016/j.neurobiolaging.2009.07.014.
17. Bezard E., Brotchie J.M., Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001, 2:577-588.
18. Blanchet P.J., Metman L.V., Chase T.N. Renaissance of amantadine in the treatment of Parkinson's disease. Adv Neurol 2003, 91:251-257.
19. Brown T., de Groote C., Brotchie J. Recent advances in the treatment of L-DOPA-induced dyskinesia. IDrugs 2002, 5:454-468.
20. Breysse N., Amalric M., Salin P. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J Neurosci 2003, 23:8302-8309.
21. Marino M.J., Williams D.L., O'Brien J.A., Valenti O., McDonald T.P., Clements M.K., et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A 2003, 100:13668-13673.
22. Breysse N., Baunez C., Spooren W., Gasparini F., Amalric M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 2002, 22:5669-5678.
23. Dekundy A., Pietraszek M., Schaefer D., Cenci M.A., Danysz W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull 2006, 69:318-326.
24. Ossowska K., Konieczny J., Wolfarth S., Pilc A. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology 2005, 49:447-455.
25. Ossowska K., Konieczny J., Wolfarth S., Wieronska J., Pilc A. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 2001, 41:413-420.
26. Spooren W.P., Gasparini F., Bergmann R., Kuhn R. Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur J Pharmacol 2000, 406:403-410.
27. Spooren W.P., Gasparini F., Salt T.E., Kuhn R. Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends Pharmacol Sci 2001, 22:331-337.
28. Gravius A., Dekundy A., Nagel J., More L., Pietraszek M., Danysz W. Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats. J Neural Transm 2008, 115:1609-1619.
29. Levandis G., Bazzini E., Armentero M.T., Nappi G., Blandini F. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 2008, 29:161-168.
30. Rylander D., Recchia A., Mela F., Dekundy A., Danysz W., Cenci M.A. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalling. J Pharmacol Exp Therapeut 2009, 330:227-235.